Bioventus Yönetim
Yönetim kriter kontrolleri 4/4
Bioventus CEO'su Rob Claypoole, Jan2024 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı $ 4.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 19.2% maaş ve 80.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler $ 2.25M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 5.5 yıldır.
Anahtar bilgiler
Rob Claypoole
İcra Kurulu Başkanı
US$4.3m
Toplam tazminat
| CEO maaş yüzdesi | 19.17% |
| CEO görev süresi | 2.6yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 3.3yrs |
| Yönetim Kurulu ortalama görev süresi | 5.5yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • Jul 07
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Summary Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 17
BVS: 2026 Sales Guidance Will Support A Higher Share Price
Analysts maintained their $16.00 price target on Bioventus, noting only minor adjustments to assumptions such as the discount rate, revenue growth outlook, profit margin, and future P/E, which were not significant enough to change their overall valuation view. What's in the News for Bioventus Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, indicating expected net sales in the range of $600 million to $610 million.
Anlatı Güncellemesi • Jun 03
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.Anlatı Güncellemesi • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).Analiz Makalesi • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...Anlatı Güncellemesi • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.Anlatı Güncellemesi • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.Anlatı Güncellemesi • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.Anlatı Güncellemesi • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.Anlatı Güncellemesi • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
Anlatı Güncellemesi • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.Anlatı Güncellemesi • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.Anlatı Güncellemesi • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.Anlatı Güncellemesi • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.Anlatı Güncellemesi • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).Anlatı Güncellemesi • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.Analiz Makalesi • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Anlatı Güncellemesi • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.Anlatı Güncellemesi • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.Anlatı Güncellemesi • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.Anlatı Güncellemesi • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.Analiz Makalesi • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...Analiz Makalesi • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...Yeni Anlatı • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Analiz Makalesi • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 28 2026 | n/a | n/a | US$28m |
| Dec 31 2025 | US$4m | US$824k | US$23m |
| Sep 27 2025 | n/a | n/a | US$10m |
| Jun 28 2025 | n/a | n/a | US$2m |
| Mar 29 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$6m | US$780k | -US$36m |
Tazminat ve Piyasa: Rob 'ın toplam tazminatı ($USD 4.30M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.57M ).
Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Rob Claypoole (54 yo)
2.6yrs
Görev süresi
US$4,299,108
Tazminat
Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, U.S for Mlnlycke Healt...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.6yrs | US$4.30m | 0.20% $ 2.2m | |
| Senior VP & CFO | 4.4yrs | US$1.90m | 0.26% $ 2.9m | |
| Senior VP | 9yrs | US$1.41m | 0.23% $ 2.5m | |
| Senior Vice President of Operations | 2.8yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations & Treasurer | no data | Veri yok | Veri yok | |
| Senior VP & Chief Compliance Officer | 6yrs | Veri yok | 0.095% $ 1.1m | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | Veri yok | Veri yok | |
| Senior VP & GM of Surgical | 1.7yrs | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
60.5yo
Ortalama Yaş
Deneyimli Yönetim: BVS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.6yrs | US$4.30m | 0.20% $ 2.2m | |
| Independent Director | 5.9yrs | US$275.00k | 0.22% $ 2.5m | |
| Independent Director | 3.6yrs | US$290.00k | 0.17% $ 1.9m | |
| Independent Director | 5.9yrs | US$215.00k | 0.17% $ 1.9m | |
| Independent Chairman of the Board | 5.9yrs | US$380.00k | 0.44% $ 4.9m | |
| Independent Director | 5.9yrs | US$277.50k | 0.17% $ 1.9m | |
| Independent Director | 5.9yrs | US$300.00k | 0.20% $ 2.3m | |
| Independent Director | 5.1yrs | US$290.00k | 0.16% $ 1.8m | |
| Independent Director | 5.9yrs | US$245.00k | 0.065% $ 727.4k | |
| Independent Director | 4.8yrs | US$282.50k | 0.16% $ 1.8m | |
| Independent Director | 4.6yrs | US$280.00k | 0.11% $ 1.3m | |
| Independent Director | less than a year | Veri yok | Veri yok |
5.5yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BVS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/04 20:11 |
| Gün Sonu Hisse Fiyatı | 2026/08/03 00:00 |
| Kazançlar | 2026/03/28 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bioventus Inc. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |